CoChat

Rivastigmine in subcortical vascular dementia

Moretti, Rita, Torre, Paola, Antonello, Rodolfo M, Cazzato, Giuseppe, Bava, Antonio · 2002 · Journal of the Neurological Sciences

The DOI matches its Crossref record; 40 of the 44 references it cites were found in a registry or an index.

Abstract

Further to recent data indicating that patients with vascular dementia (VaD) show a cholinergic deficit, we aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the symptoms of VaD. Patients aged 65-80, with a diagnosis of dementia and probable VaD, received rivastigmine 3-6 mg/day (n=8) or cardioaspirin (n=8) in an open study for 22 months. At 22 months, patients treated with rivastigmine showed significant improvements in executive function and behavioural symptoms (both p<0.05 vs. both baseline and control group), which were reflected in reduced caregiver stress (p<0.05 vs. baseline and controls). Baseline scores of global response, cognition, word fluency and activities of daily living were maintained in patients receiving rivastigmine, and there was no increase in benzodiazepine or neuroleptic intake. In contrast, the control group showed no improvements in any domain, and significant deterioration in global response and executive function (both p<0.05 vs. baseline and rivastigmine group). Side effects in both groups were tolerable and there were no study withdrawals. Long-term rivastigmine treatment appeared to be safe and effective in this patient population. In particular, improvements in domains particularly relevant to this condition were observed. These benefits may reflect the drug's dual inhibitory effects on the cholinergic system, and its particular activity in frontal areas of the brain. A large, double-blind study of rivastigmine in patients with VaD would be worthwhile.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0022-510x(02)00280-0

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Wallin, 1989, Neurochemical abnormalities in vascular dementia, Dementia, 1, 120

Cited by

See all 108

Metadata

Authors
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A.
Affiliations
University of Trieste (IT)
Venue
Journal of the Neurological Sciences
Publisher
Elsevier BV
Published
2002-11
Volume
203-204
Pages
141-146
ISSN
0022-510X (ISSN-L)
OpenAlex
W2184923050
Cited by
107
References
44
Citations by year
2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
8.74
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the Neurological Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
Funders
National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
rivastigmine, vascular dementia, subcortical vascular dementia, acetylcholinesterase inhibitors, butyrylcholinesterase inhibition, cholinergic deficit, executive function, behavioural symptoms, caregiver stress, long-term drug safety
MeSH terms
Rivastigmine, Activities of Daily Living, Aged, Aged, 80 and over, Behavior, Carbamates, Cholinesterase Inhibitors, Female, Follow-Up Studies, Humans, Male, Neuropsychological Tests, Psychiatric Status Rating Scales, Stress, Psychological, Dementia, Vascular, Treatment Outcome, Caregivers, Neuroprotective Agents, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivastigmine in subcortical vascular dementia. https://app.cochat.ai/papers/10.1016/s0022-510x(02)00280-0
The paper
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002). Rivastigmine in subcortical vascular dementia. Journal of the Neurological Sciences. https://doi.org/10.1016/s0022-510x(02)00280-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.